By preventing the communication between tumor and T-cell immunological checkpoints, anti-PD-1/PD-L1 therapy could restore T-cell function and increase proliferation, enhancing the antineoplastic immune response [31–33]. The gene discussed is CD274; the disease is neoplasm.